The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato.
The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent version of ketamine.
READ: AI can diagnose depression better than doctors
Article continues after this advertisementSpravato doesn’t work for everyone, but it can be life-changing to some.
“We see that e-commerce is one that is a rapidly changing environment. So we’re adapting to the needs of e-commerce. Semiconductors still play a role because before you get into the internet you will need the computers and laptops that they produces,” FedEx Philippines managing director Maribeth Espinosa told reporters on Friday.
By Jan. 1, 2025, the prices will go up by 5.9 percent on average. This is higher than the 4.9-percent uptick set this year.
FEATURED STORIES TECHNOLOGY Study reveals two effective ways to relieve work fatigue TECHNOLOGY Venice AI: The free, uncensored and private ChatGPT alternative TECHNOLOGY World’s first anti-depression nasal spray receives FDA approval How does the anti-depression nasal spray work?The FDA has expanded approval for a nasal spray known as Spravato, a brand name for #esketamine, to treat people with severe #depression. Dr. Yvette I. Sheline noted how esketamine differs from existing drugs for depression. https://t.co/nJ8M0Kd9lk
— Penn Medicine (@PennMedicine) January 24, 2025Johns Hopkins Medicine says Spravato boosts serotonin, norepinephrine and dopamine levels, similar to regular antidepressants.
However, this new medicine increases glutamate, the most abundant chemical messenger in the brain.
Article continues after this advertisementAs a result, the anti-depression nasal spray has a greater impact on more brain cells than conventional antidepressants.
Article continues after this advertisementIt’s available as a monotherapy, but Johns Hopkins says patients must take it with a conventional antidepressant.
Article continues after this advertisementEsketamine should only provide rapid relief from depression symptoms until other medications take effect.
The first dose can distort a patient’s perception. That’s why they take the initial dose in a clinic, and doctors must observe them for two hours.
Article continues after this advertisementThen, the patient takes three doses of the anti-depression nasal spray every five minutes under a doctor’s supervision.
The patient remains in the clinic under observation until potential side effects have subsided.
Side effects include hallucinations, feelings of being disconnected from reality, and headaches.
If esketamine seems familiar, that’s probably because it’s a component of ketamine. It was once popular as a party drug called Special K.
Fortunately, Spravato underwent 31 clinical trials over the past six years and a phase 4 trial, which approved it for monotherapy use.
big slots 777“Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them,” said Johnson & Johnson neuroscientist Bill Martin.
Subscribe to our daily newsletter
“For more than six years, I’ve seen firsthand the real-world impact Spravato can have on patients’ lives22win,” says psychiatrist Gregory Mattingly, who was part of the original clinical trials on the drug.
TOPICS: technology READ NEXT Study reveals two effective ways to relieve work fatigue OpenAI Deep Research makes research papers for you EDITORS' PICK SWS trust ratings for Marcos, Duterte continue to drop Cocopea quits NTF-Elcac, cites academic freedom NBA: Spurs acquire De'Aaron Fox, Kings get Zach LaVine PNP: 21 cops in P6.7-B shabu case now under custody EDITORIAL: Magic number for a just living wage Ban on ‘ayuda’ distribution 10 days before polls eyed MOST READ BSP eyes shift away from OTPs to fight fraud Dela Rosa last passenger to board chopper which crashed in Nueva Ecija SWS trust ratings for Marcos, Duterte continue to drop Big biz group joins call to stop P200 wage hike Follow @FMangosingINQ on Twitter --> View comments